Rhabdomyosarcoma
Epidemiology And Risk Factors
- Constitutes 40% of soft-tissue sarcomas (STS); most common pediatric STS.
- Incidence: 4-5 per million children <15 years.
- Represents third most common solid extracranial tumor (following neuroblastoma, Wilms tumor).
- Age distribution: 60% diagnosed <10 years age.
- Male predominance (1.4:1 ratio).
- Genetic predispositions: Li-Fraumeni syndrome (p53 mutation), Neurofibromatosis Type 1 (NF1), Beckwith-Wiedemann syndrome, Costello syndrome.
- DICER1 mutations strongly associated with embryonal variant.
- Environmental triggers: Parental marijuana/cocaine use, first-trimester prenatal X-ray exposure.
Pathological And Genetic Classification
Diagnosis requires immunohistochemistry (actin, desmin, myogenin) and molecular cytogenetics.
| Subtype | Anatomic Predilection | Age | Molecular Genetics | Morphologic Features |
|---|---|---|---|---|
| Embryonal (ERMS) | Head/neck, genitourinary, orbit | 3-12 years | Loss of heterozygosity (LOH) at 11p15.5 causing IGF-II overproduction | Resembles 7-10 week fetal skeletal muscle. Loose myxoid stroma. |
| Alveolar (ARMS) | Extremities, trunk, perineum | 6-21 years | FOXO1-PAX3 (2q35, 75%) or FOXO1-PAX7 (1p36, 25%) translocations | Resembles 10-21 week fetal muscle. Dense alveolar pattern. |
| Botryoid | Bladder, vagina, nasopharynx | 0-8 years | ERMS variant | Grape-like macroscopic appearance. Cambium layer on microscopy. |
| Spindle Cell | Paratesticular, head/neck | 2-12 years | NCOA2 translocations (infantile). MYOD1 mutations (poor prognosis) | Spindle-shaped cells, collagen-rich stroma. Distinct clinical behavior. |
Note: PAX-FOXO1 fusion indicates poor prognosis. "Fusion-negative" ARMS clinically behaves identical to ERMS.
Clinical Manifestations
Presents universally as painless enlarging mass. Roughly 20% present with metastases (lung, bone marrow, nodes, bone).
| Primary Site | Clinical Signs And Symptoms |
|---|---|
| Parameningeal (Head/Neck) | Infiltrates skull base. Cranial nerve palsies, meningeal signs, increased intracranial pressure. |
| Orbit | Proptosis, ocular palsies, conjunctival mass. |
| Genitourinary (Female) | Sarcoma botryoides protruding from vagina/cervix, vaginal bleeding. |
| Genitourinary (Male) | Bladder/prostate: Urinary obstruction, hematuria. Paratesticular: Painless scrotal mass. |
| Other Sites | Biliary tract (obstructive jaundice), retroperitoneum (abdominal mass, obstruction). |
Diagnostic Evaluation
- Biopsy: Incisional or multiple core needle biopsies mandatory. Fine-needle aspiration unacceptable. Resect biopsy tracks during definitive surgery.
- Laboratory: Complete blood count, comprehensive metabolic panel. LDH serves as tumor burden marker.
- Local Imaging: Magnetic Resonance Imaging (MRI) defines primary tumor extent.
- Metastatic Surveillance: Chest Computed Tomography (CT) for lung metastasis. 18F-FDG PET replaces bone scan for osseous/metastatic spread.
- Bone Marrow: Bilateral aspiration and biopsy (omitted in node-negative, noninvasive ERMS without lung spread).
- Nodal Assessment: Sentinel lymph node biopsy required for all extremity primaries. Ipsilateral retroperitoneal lymph node dissection mandatory for paratesticular primaries in boys >10 years.
Staging And Risk Stratification
Management dictated by Risk Group classification, derived from anatomic site, TNM stage, and Postoperative Clinical Group.
Postoperative Clinical Grouping (Intergroup Rhabdomyosarcoma Study)
| Group | Surgical / Pathologic Status | Frequency |
|---|---|---|
| Group I | Localized disease, completely resected, negative margins | 16% |
| Group II | Microscopic residual disease (positive margins) OR positive regional nodes completely resected | 20% |
| Group III | Gross residual disease (post-biopsy or incomplete resection >50%) | 48% |
| Group IV | Distant metastasis present at diagnosis | 16% |
Management Principles
Requires multimodal integration of surgery, radiation, and chemotherapy.
Local Control Modalities
- Surgery: Complete wide local excision with negative margins preferred. Aggressive mutilating surgeries (enucleation, amputation, radical head/neck dissection) explicitly avoided; rely instead on chemoradiation.
- Radiation Therapy: Indicated for all ARMS, and ERMS with residual microscopic/gross disease (Groups II and III). Administered at week 13. Doses range from 36 Gy (microscopic residual) to 50.4 Gy (gross residual).
Systemic Chemotherapy
- Eradicates micrometastatic disease universally present at diagnosis.
- Standard Backbone (VAC): Vincristine, Actinomycin D (Dactinomycin), Cyclophosphamide.
- Low-Risk Disease: Reduced therapy (VAC + VA) yields excellent event-free survival (85-95%).
- Intermediate-Risk Disease: VAC alternating with Vincristine/Irinotecan (VI). Prolonged maintenance with IV Vinorelbine and oral Cyclophosphamide improves survival.
- High-Risk Disease (Metastatic): Interval-compressed intensive regimens (VAC/VI/VDC/IE) ± maintenance. Prognosis remains poor (Event-free survival 5-20% for fusion-positive).# Rhabdomyosarcoma
Epidemiology And Risk Factors
- Constitutes 40% of soft-tissue sarcomas (STS); most common pediatric STS.
- Incidence: 4-5 per million children <15 years.
- Represents third most common solid extracranial tumor (following neuroblastoma, Wilms tumor).
- Age distribution: 60% diagnosed <10 years age.
- Male predominance (1.4:1 ratio).
- Genetic predispositions: Li-Fraumeni syndrome (p53 mutation), Neurofibromatosis Type 1 (NF1), Beckwith-Wiedemann syndrome, Costello syndrome.
- DICER1 mutations strongly associated with embryonal variant.
- Environmental triggers: Parental marijuana/cocaine use, first-trimester prenatal X-ray exposure.
Pathological And Genetic Classification
Diagnosis requires immunohistochemistry (actin, desmin, myogenin) and molecular cytogenetics.
| Subtype | Anatomic Predilection | Age | Molecular Genetics | Morphologic Features |
|---|---|---|---|---|
| Embryonal (ERMS) | Head/neck, genitourinary, orbit | 3-12 years | Loss of heterozygosity (LOH) at 11p15.5 causing IGF-II overproduction | Resembles 7-10 week fetal skeletal muscle. Loose myxoid stroma. |
| Alveolar (ARMS) | Extremities, trunk, perineum | 6-21 years | FOXO1-PAX3 (2q35, 75%) or FOXO1-PAX7 (1p36, 25%) translocations | Resembles 10-21 week fetal muscle. Dense alveolar pattern. |
| Botryoid | Bladder, vagina, nasopharynx | 0-8 years | ERMS variant | Grape-like macroscopic appearance. Cambium layer on microscopy. |
| Spindle Cell | Paratesticular, head/neck | 2-12 years | NCOA2 translocations (infantile). MYOD1 mutations (poor prognosis) | Spindle-shaped cells, collagen-rich stroma. Distinct clinical behavior. |
Note: PAX-FOXO1 fusion indicates poor prognosis. "Fusion-negative" ARMS clinically behaves identical to ERMS.
Clinical Manifestations
Presents universally as painless enlarging mass. Roughly 20% present with metastases (lung, bone marrow, nodes, bone).
| Primary Site | Clinical Signs And Symptoms |
|---|---|
| Parameningeal (Head/Neck) | Infiltrates skull base. Cranial nerve palsies, meningeal signs, increased intracranial pressure. |
| Orbit | Proptosis, ocular palsies, conjunctival mass. |
| Genitourinary (Female) | Sarcoma botryoides protruding from vagina/cervix, vaginal bleeding. |
| Genitourinary (Male) | Bladder/prostate: Urinary obstruction, hematuria. Paratesticular: Painless scrotal mass. |
| Other Sites | Biliary tract (obstructive jaundice), retroperitoneum (abdominal mass, obstruction). |
Diagnostic Evaluation
- Biopsy: Incisional or multiple core needle biopsies mandatory. Fine-needle aspiration unacceptable. Resect biopsy tracks during definitive surgery.
- Laboratory: Complete blood count, comprehensive metabolic panel. LDH serves as tumor burden marker.
- Local Imaging: Magnetic Resonance Imaging (MRI) defines primary tumor extent.
- Metastatic Surveillance: Chest Computed Tomography (CT) for lung metastasis. 18F-FDG PET replaces bone scan for osseous/metastatic spread.
- Bone Marrow: Bilateral aspiration and biopsy (omitted in node-negative, noninvasive ERMS without lung spread).
- Nodal Assessment: Sentinel lymph node biopsy required for all extremity primaries. Ipsilateral retroperitoneal lymph node dissection mandatory for paratesticular primaries in boys >10 years.
Staging And Risk Stratification
Management dictated by Risk Group classification, derived from anatomic site, TNM stage, and Postoperative Clinical Group.
Postoperative Clinical Grouping (Intergroup Rhabdomyosarcoma Study)
| Group | Surgical / Pathologic Status | Frequency |
|---|---|---|
| Group I | Localized disease, completely resected, negative margins | 16% |
| Group II | Microscopic residual disease (positive margins) OR positive regional nodes completely resected | 20% |
| Group III | Gross residual disease (post-biopsy or incomplete resection >50%) | 48% |
| Group IV | Distant metastasis present at diagnosis | 16% |
Management Principles
Requires multimodal integration of surgery, radiation, and chemotherapy.
Local Control Modalities
- Surgery: Complete wide local excision with negative margins preferred. Aggressive mutilating surgeries (enucleation, amputation, radical head/neck dissection) explicitly avoided; rely instead on chemoradiation.
- Radiation Therapy: Indicated for all ARMS, and ERMS with residual microscopic/gross disease (Groups II and III). Administered at week 13. Doses range from 36 Gy (microscopic residual) to 50.4 Gy (gross residual).
Systemic Chemotherapy
- Eradicates micrometastatic disease universally present at diagnosis.
- Standard Backbone (VAC): Vincristine, Actinomycin D (Dactinomycin), Cyclophosphamide.
- Low-Risk Disease: Reduced therapy (VAC + VA) yields excellent event-free survival (85-95%).
- Intermediate-Risk Disease: VAC alternating with Vincristine/Irinotecan (VI). Prolonged maintenance with IV Vinorelbine and oral Cyclophosphamide improves survival.
- High-Risk Disease (Metastatic): Interval-compressed intensive regimens (VAC/VI/VDC/IE) ± maintenance. Prognosis remains poor (Event-free survival 5-20% for fusion-positive).